These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 7905915)

  • 1. Manipulation and exploitation of the tumour environment for therapeutic benefit.
    Stratford IJ; Adams GE; Bremner JC; Cole S; Edwards HS; Robertson N; Wood PJ
    Int J Radiat Biol; 1994 Jan; 65(1):85-94. PubMed ID: 7905915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour hypoxia: the picture has changed in the 1990s.
    Brown JM; Giaccia AJ
    Int J Radiat Biol; 1994 Jan; 65(1):95-102. PubMed ID: 7905916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P; Stratford IJ
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anemia and radiotherapy].
    Pasquier D; Lartigau E
    Bull Cancer; 2003 Apr; 90 Spec No():S152-7. PubMed ID: 12856427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioreductive drugs in cancer therapy.
    Stratford IJ
    BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
    [No Abstract]   [Full Text] [Related]  

  • 7. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC; Stratford IJ; Bowler J; Adams GE
    Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia as a target for combined modality treatments.
    Wouters BG; Weppler SA; Koritzinsky M; Landuyt W; Nuyts S; Theys J; Chiu RK; Lambin P
    Eur J Cancer; 2002 Jan; 38(2):240-57. PubMed ID: 11803141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioreductive mechanisms.
    Workman P
    Int J Radiat Oncol Biol Phys; 1992; 22(4):631-7. PubMed ID: 1544830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
    Brown JM
    Mol Med Today; 2000 Apr; 6(4):157-62. PubMed ID: 10740254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
    Brown JM
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirapazamine: from bench to clinical trials.
    Marcu L; Olver I
    Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The Oxygen effect: an old new target?].
    Lartigau E; Dewas S; Gras L
    Cancer Radiother; 2008 Jan; 12(1):42-9. PubMed ID: 18261946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Radiation sensitizing agents for hypoxic cells: past, present and future].
    Lartigau E
    Cancer Radiother; 1998 Dec; 2(6):775-80. PubMed ID: 9922787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor microenvironment: a double-edged sword.
    Siemann DW
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):697-9. PubMed ID: 9845079
    [No Abstract]   [Full Text] [Related]  

  • 17. Sensitization of hypoxic tumour cells--clinical experience.
    Overgaard J
    Int J Radiat Biol; 1989 Nov; 56(5):801-11. PubMed ID: 2573679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
    Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
    Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relevance of tumour pH to the treatment of malignant disease.
    Wike-Hooley JL; Haveman J; Reinhold HS
    Radiother Oncol; 1984 Dec; 2(4):343-66. PubMed ID: 6097949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
    Cole S; Stratford IJ; Adams GE
    Int J Radiat Biol; 1989 Nov; 56(5):587-91. PubMed ID: 2573651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.